Optimizerx Corp Stock Price, News & Analysis

OptimizeRx Corp. (Nasdaq: OPRX) reported impressive preliminary revenue for Q3 2020, exceeding $10 million, a 100% year-over-year increase. The company anticipates positive non-GAAP net income for the quarter due to organic growth driven by enterprise deals and tactical programs. The revenue for the first nine months surged over 53% to $26.4 million. The CEO noted a strategic focus on expanding physician and patient reach, attributing growth to increased enterprise agreements. Full Q3 results will be disclosed in early November.

OptimizeRx Corp (Nasdaq: OPRX) is set to resume its webinar series, focusing on improving medication launches with industry experts. Scheduled for September 24 at 1:00 p.m. ET, the webinar will address patient adherence challenges due to side effects of new medications. In collaboration with the Digital Health Coalition and Diligent Health Solutions, the session will explore a successful patient engagement case study and innovative strategies for life science companies. The webinar is free to industry professionals and aims to enhance patient outcomes.

OptimizeRx Corp. (Nasdaq: OPRX) has partnered with Epion Health to enhance patient access to savings programs prior to medical appointments. Patients using Epion’s digital check-in can now connect with OptimizeRx for real-time medication cost-saving opportunities based on their health records. This integration aims to facilitate conversations about affordability between patients and providers, thereby improving treatment outcomes. The partnership is expected to launch next month, expanding services to health systems nationwide, benefiting over 10 million patient appointments annually.

OptimizeRx Corp. (Nasdaq: OPRX), a leader in digital health solutions, is set to participate in two key investor conferences in September. The first event is the H.C. Wainwright’s 22nd Annual Global Investment Conference from September 14-16, featuring 1x1 meetings and a live webcast on September 16 at 1:00 p.m. EDT. The second event is the Lake Street Capital Markets’ 4th Annual Best Ideas Growth Conference on September 17, emphasizing further engagement with institutional investors.

Management will highlight the expansion of its digital health platform and its new FDA-cleared Smart Health Stations, enhancing communication between life science companies, healthcare providers, and patients.

OptimizeRx Corp. (NASDAQ: OPRX) has been invited to present at the LD 500 virtual investor conference from September 1-4, 2020. CEO William Febbo will present on September 3 at 12:20 p.m. Eastern time and will engage in one-on-one meetings with institutional investors. The conference will showcase over 300 micro-cap companies and feature discussions relevant to investors. OptimizeRx aims to highlight its digital health solutions that enhance communication between life science companies, physicians, and patients, particularly with its new network of 10,000 Smart Health Stations.

OptimizeRx Corp. (Nasdaq: OPRX) has expanded its digital health communication network in partnership with Change Healthcare (Nasdaq: CHNG). This collaboration enhances access to vital healthcare information for providers, enabling them to deliver real-time updates on drug savings and treatment options during patient consultations. The integration supports better patient-provider communication, aiming to improve patient outcomes. The Intelligent Healthcare Network™ by Change Healthcare processes 14 billion transactions annually, showcasing a robust platform for data exchange.

OptimizeRx Corp. (Nasdaq: OPRX) will hold a conference call on August 5, 2020, at 4:30 p.m. ET to discuss its Q2 2020 results. The call will be hosted by management, following the release of financial results. Interested participants can dial in using the provided toll-free and international numbers. A replay will be available after the call and can be accessed via the OptimizeRx website. The company specializes in digital health solutions for life sciences and payers, improving communication and patient engagement within healthcare.

OptimizeRx Corp. (Nasdaq: OPRX) has appointed Greg Wasson, former president and CEO of Walgreens Boots Alliance, to its board of directors. This strategic move aims to bolster patient connectivity and enhance digital health services. Wasson, credited for achieving $76.4 billion in sales at Walgreens, brings extensive experience in organizational change and leadership. CEO William Febbo highlighted the growing need for affordability and adherence in digital health, making Wasson's expertise crucial for the company's future growth.

OptimizeRx Corp. (Nasdaq: OPRX) announced securing two new enterprise-level SaaS engagements, one from a new client and another transitioning from a legacy system, averaging an annual contract value of $3.6 million. The company highlights strong revenue potential from converting legacy clients to its enterprise platform, estimating over $100 million in upsell opportunities. CEO William Febbo noted the increasing demand for their digital health solutions amid COVID-19, enhancing communication among pharmaceutical companies, healthcare providers, and patients, thereby improving medication affordability and adherence.